The more #atopicdermatitis lesions a patient has, the more severe the patient's disease and the more likely the patient is to have poor disease control and a decreased quality of life, a new study shows. Read more here: scholarsinmedicine.com/latest-news/86
$CRVS #atopicdermatitis Ph 1 trial w/ ITKi #soquelitinib derisked:
1. Safety data 2+ yrs, #PTCL trial (unusual to have long-term safety already)
2. Dog AD study: 5/5 dogs responded w/in 14 days
3. Dosing 100mg BID => 400mg QD, 28 days
4. Data open to $CRVS, could report anytime!
Research from 2022 identifies specific patterns of immune cell behavior for diverse skin diseases—such as #AtopicDermatitis and #Psoriasis —and can be used by dermatologists in the clinic.
Check out it out: scim.ag/6Lg #WeekendReads
Children with #AtopicDermatitis (AD) may be at a higher risk for #CognitiveImpairment , including difficulties with #Learning and #Memory , particularly if they have concurrent #ADHD or a #Learning Disability. Study in JAMA Dermatology
Read here: brnw.ch/21wJmvt
#MedTwitter
Eczema is unique to each individual. ✨
Browse the Atopic Dermatitis Visual Guide to view a broader spectrum of #eczema on various skin tones and body parts: nationaleczema.org/visual-guide/
#GetEczemaWise #atopicdermatitis #unhideECZEMA #skindisease #skincondition #skinhealth
$CRVS #Soquelitinib significant advantages over current #atopicdermatitis #asthma therapies:
SQL oral vs monoclonal antibodies subcutaneous/IV
SQL blocks 8-10 cytokines at once vs only 1-2 by others
SQL is upstream blocks #Th2 , #Th17 cells
SQL very safe as shown in #PTCL trial
JUST IN: Topline data from our Phase 3b/4 head-to-head study in #AtopicDermatitis announced today. Read more: bit.ly/4dcFGFk #immunology
Discover the three main factors negatively impacting growth for children with atopic dermatitis here: hubs.la/Q02vn22c0
#AAD #Dermatology #AtopicDermatitis
Corvus Pharmaceutical $CRVS started Phase 1 trial w/ #Soquelitinib in #atopicdermatitis . Offers significant advantages over current injectable antibody therapies: SQL oral vs subcutaneous/IV
SQL blocks 8-10 chemical messengers at once vs only 1-2 by others
corvuspharma.gcs-web.com/news-releases/…
Corvus Pharmaceutical $CRVS started Phase 1 trial w/ #Soquelitinib in #atopicdermatitis #eczema .
Advantages over current injectable antibody therapies: SQL oral vs subcutaneous/IV
SQL blocks 8-10 chemical messengers at once
SQL stops Th2, Th17 cells
corvuspharma.gcs-web.com/news-releases/…
Corvus Pharmaceutical $CRVS started Phase 1 trial w/ #Soquelitinib in #atopicdermatitis #eczema .
Advantages over current injectable antibody therapies: SQL oral vs subcutaneous/IV
SQL blocks 8-10 chemical messengers at once
SQL stops Th2, Th17 cells
corvuspharma.gcs-web.com/news-releases/…
Read the May issue Editorial from JID Editors Sara J Brown (MTSR Editor) Sara 💙💛 🇺🇦 and Johann E Gudjonsson (Reviews Editor):
Halting the Vicious Cycle of #atopicdermatitis : Empowered by Scientific Understanding
doi.org/10.1016/j.jid.…
#dermtwitter #dermatology #dermscience
NEWS: Upadacitinib (Rinvoq, AbbVie) bested dupilumab (Dupixent, Sanofi and Regeneron Pharma) in adults and adolescents with moderate-to-severe #atopicdermatitis who had an inadequate response to or couldn’t tolerate systemic therapy, according to LEVEL UP. thedermdigest.com/rinvoq-bests-d…